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Abstract 
 
Histone deacetylase (HDAC) inhibitors are a class of promising new 
multifunctional anticancer agents. These agents are able to affect multiple 
epigenetic changes in aberrant cells. In addition to regulating the gene 
expression and transcription via chromatin remodeling, HDAC inhibitors 
can also modulate a variety of cellular functions including proliferation, 
differentiation, and apoptosis. Vorinostat (SuberAniloHydroxamic Acid, 
SAHA), the first HDAC inhibitor approved by FDA, inhibited the metastasis 
of various cancer cells. However, SAHA distributes in cancer tissue and 
normal tissue in a similar level. It will be ideal to selectively delivery SAHA 
into cancer cells. Rapidly growing cancer cells have a great need for 
cholesterol to generate new membranes. Increased low-density lipoprotein 
(LDL)-uptake by tumor cells has been found. LDL is the major cholesterol 
carrier in plasma and its uptake is mediated by the LDL-receptor (LDL-R), a 
glycoprotein overexpressed on the surface of cancer cells. Cholesterol can be 
used as a delivery agent to enhance anti-cancer drugs penetrating cancer cell 
membrane via LDL-R. Degradation of LDL particles by endosomal enzymes 
will result in the release of the conjugates to target cancer cells. Herein, we 
designed and synthesized SAHA cholesterol conjugate, and tested the anti-
cancer activity of SAHA and its conjugate. The results suggest that cancer 
cells uptake more cholesterol SAHA conjugate when the culture medium 
does not contain LDL. Based on the information, we will design and 
generate artificial LDL containing SAHA cholesterol conjugate to enhance 
the drug delivery.  
 
  
